Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting
These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.
- These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.
- Anemia is the most common adverse effect of CD47-targeting molecules, since red blood cells also express CD47.
- Moreover, modifying the RNA sequence of the prospective anti-CD47 molecule is far more efficient than engineering the final protein product.
- Our platform has made it possible for Nutcracker to lay a strong and early foundation for our future therapeutic work.”